Addison disease (primary adrenal insufficiency)

What changes during this transition

Addison disease is destruction of the adrenal cortex itself — primary adrenal insufficiency. The end-organ that makes cortisol, aldosterone, and adrenal androgens is gone or going. Autoimmune adrenalitis (21-hydroxylase antibodies) accounts for roughly 80% of cases in developed countries; tuberculosis was historically dominant and remains so in some jurisdictions; CMV/HIV, metastatic disease, bilateral adrenalectomy, congenital adrenal hyperplasia, adrenoleukodystrophy (X-linked males), drugs (etomidate, ketoconazole, mitotane), and the polyendocrine syndromes (APS-1 via AIRE mutations, APS-2 via HLA-DR3) round out the differential. This is editorially the most load-bearing substrate in the adrenal family because the gap between what peptides claim and what Addison patients need is total. Hydrocortisone and fludrocortisone replacement is not a lifestyle intervention — it is the difference between life and death. Adrenal crisis (hypotension, shock, hyperkalemia, hyponatremia, hypoglycemia, altered mental status) carries significant mortality without rapid IV hydrocortisone, and crisis can be precipitated by infection, surgery, trauma, dehydration, or — most commonly — missed or under-dosed replacement doses during stress. Every Addison patient needs an emergency injection kit (Solu-Cortef 100 mg vial), a medical alert identifier, and a written sick-day rules plan. Stress dosing (2-3x maintenance for febrile illness, IV hydrocortisone for surgery/trauma) is built into the diagnosis from day one. Diagnostically, Addison is distinguished from SECONDARY adrenal insufficiency (pituitary ACTH deficiency) by elevated plasma ACTH, hyperpigmentation of palmar creases / scars / buccal mucosa (ACTH/MSH cross-reactivity at the melanocortin receptor), aldosterone deficiency with elevated plasma renin, and the broader autoimmune-comorbidity pattern (vitiligo, autoimmune thyroid, type 1 diabetes, premature ovarian insufficiency — the APS clusters). Confirmation is the ACTH stimulation test (cosyntropin 250 mcg with 30- and 60-minute cortisol response under 18 µg/dL); 21-hydroxylase antibodies establish autoimmune etiology; very long chain fatty acids screen for adrenoleukodystrophy in male patients without antibodies. Standard of care anchors are the Endocrine Society 2016 clinical practice guideline and the European Society of Endocrinology 2024 update: hydrocortisone 15-25 mg/day divided BID-TID (or modified-release Plenadren, or — for 21-hydroxylase-deficient CAH specifically — Chronocort/Efmody, FDA-approved December 2021 as a dual-release hydrocortisone); fludrocortisone 0.05-0.2 mg/day for mineralocorticoid replacement; DHEA replacement remains controversial but has a quality-of-life signal in women. The emerging entrant is crinecerfont (Crenessity), FDA-approved December 2024 as a CRF1 receptor antagonist that reduces hydrocortisone requirements in 21-hydroxylase-deficient CAH — relevant to the CAH subset of primary adrenal insufficiency, not classical autoimmune Addison. Peptides do not appear in any guideline for Addison disease. The community framings users encounter — 'BPC-157 for adrenal healing,' 'NMN for adrenal cortisol support,' 'thymosin alpha-1 for autoimmune modulation' — fail at the mechanism level. You cannot regenerate a destroyed adrenal cortex with a regenerative peptide. You cannot supply absent cortisol with a NAD+ precursor. And in autoimmune adrenalitis specifically, T-cell-activating immunomodulators move in the wrong direction — they amplify the ongoing destruction rather than dampening it. The peptide conversation in Addison is a conversation about why the conversation is itself the wrong frame. Resources for patients and clinicians: NADF (National Adrenal Diseases Foundation), AIM-HI (Addison's International), the Pituitary Foundation (for the broader adrenal-pituitary patient population). Emergency injection training is widely available through endocrinology clinics and these patient organizations.